Barclays thinks Relay Therapeutics stock can benefit from progress in drug tests to get a proposed breast cancer treatment approved, boosting the stock.
Relay stock has slumped 40% in 2024.
"We believe the 2H update will help show the superior efficacy/safety profile for Relay's PI3Kalpha (RLY-2608) over existing PI3Kalpha inhibitors like alpelisib and inavolisib," Lawson said.
Barclays sees a 70% chance of positive data emerging from an expanded Phase 1 study of RLY-2608 (+fulvestrant) in advanced HR+/HER2- breast cancer.
That outcome, "all else equal, could potentially drive the stock up $5 while negative data could drive the stock down $2," the bank said.
Persons:
Peter Lawson, Relay's, Lawson
Organizations:
Barclays, Therapeutics